AI-Driven Genotype Prediction Using EHR and Multimodal Data
Predicting Patient Genotypes Using Electronic Health Records and Multimodal Data Through AI-Based Models
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Fei Liu, MD
- Phone Number: +86 13810512704
- Email: liufei_2359@163.com
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China
- Recruiting
- Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
-
Contact:
- Yunfang Yu
- Phone Number: +86 020-81332199
- Email: yuyf9@mail.sysu.edu.cn
-
Guangzhou, Guangdong, China
- Recruiting
- Sun Yat-sen University Cancer Hospital
-
Contact:
- Yuxing Lu
- Phone Number: +86 13161233730
- Email: yxlu0613@gmail.com
-
-
Zhejiang
-
Wenzhou, Zhejiang, China
- Recruiting
- Second Affiliated Hospital of Wenzhou Medical University
-
Contact:
- Sian Liu
- Phone Number: +86-0577-88002888
- Email: liusan@mail3.sysu.edu.cn
-
Wenzhou, Zhejiang, China
- Completed
- First Affiliated Hospital of Wenzhou Medical University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Participants must have comprehensive electronic health records (EHR), including medical history, lab results, and relevant imaging data (e.g., X-rays, MRIs, CT scans).
- Participants must have existing genetic testing data available for comparison, if applicable.
- Participants must be willing to provide consent for the use of their health data in the study.
- Participants must have no active intervention related to genetic testing or prediction during the study period.
- Participants should have complete and verifiable health data to allow for accurate prediction by the AI model.
Exclusion Criteria:
- Participants without available EHR, lab results, or imaging data.
- Participants with ambiguous, inaccurate, or unverifiable genetic testing results that cannot be used for comparison.
- Patients with significant discrepancies or missing data that would prevent the AI model from making accurate predictions.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
AI-Based Genotype Prediction Using EHR and Multimodal Data
This cohort consists of patients whose historical health data, including electronic health records (EHR), clinical lab results, and multimodal imaging data (such as X-rays, MRIs, and CT scans), will be analyzed by an AI-based prediction model to predict their genotype.
There are no active interventions in this cohort, as the study aims to use non-genetic health data to infer genetic information.
Participants will not undergo genetic testing but will provide their health data for analysis by the AI system.
The goal of this group is to assess the accuracy of the AI model in predicting genotypes and identifying genetic predispositions to various diseases based on available health data.
|
The intervention in this study involves an AI-based predictive model designed to analyze and integrate patient electronic health records (EHR), clinical lab results, and multimodal imaging data (e.g., X-rays, MRIs, CT scans).
The AI model is trained to predict a patient's genotype based on these non-genetic data sources.
This model uses machine learning algorithms to detect patterns and infer genetic information that would traditionally require direct genetic testing.
There are no active treatments or genetic tests involved in this intervention; rather, the AI system serves as a tool to predict genetic information from available clinical data, offering a non-invasive and potentially more accessible alternative to genetic testing.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Area Under the Curve (AUC)
Time Frame: 1 year
|
AUC of the ROC curve, used to quantify diagnostic accuracy.
No unit (a ratio or percentage, typically expressed as a number between 0 and 1).
|
1 year
|
|
F1 Score
Time Frame: 1 year
|
The F1 score is the harmonic mean of precision and sensitivity (recall).
It is a good measure of the model's ability to identify both true positives and minimize false positives, especially in cases where the classes are imbalanced (e.g., when the number of healthy cases is much higher than disease cases).
The F1 score ranges from 0 to 1, with 1 indicating perfect precision and recall.
|
1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sensitivity (True Positive Rate)
Time Frame: 1 year
|
Sensitivity measures how well the AI model identifies true positive cases, such as correctly diagnosing pregnant women with complications or identifying neonatal disorders.
|
1 year
|
|
Specificity (True Negative Rate)
Time Frame: 1 year
|
Specificity measures the ability of the AI model to correctly identify cases without diseases, ensuring that healthy mothers and infants are correctly identified as negative.
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- Genotype
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.